潜在性結核検査市場 – 2029年までの世界予測

Report Overview

The latent TB testing market will rise in value from estimated USD 582.5 million in 2024 to USD 773.4 million in 2029, at a CAGR of 5.8% over the forecast period.

潜在性結核検査市場は、2024年の推定5億8,250万米ドルから2029年には7億7,340万米ドルまで、予測期間中に5.8%のCAGRで増加すると予想されます。

Increased funding and grants for TB control programs across the globe have emerged as an important growth factor in the latent TB testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of TB, especially in terms of early detection and prevention. These funds are being channeled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of latent TB. Apart from that, research grants and international collaborations are also enabling TB testing integration into routine healthcare services.  Thus, this growing funding is rendering latent TB tests available and enhancing the efforts to control TB globally. This, in turn, is fuelling the growth of the global latent TB testing market.

“Interferon gamma release assay (IGRA) segment is expected to have the fastest growth rate in the latent TB testing market, by test type, during the forecast period.”

The latent TB testing market is segmented into tuberculin skin test (TST) and interferon gamma release assay (IGRA), based on test type. Interferon gamma release assay (IGRA) tests are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy than conventional tuberculin skin tests (TST); IGRA tests do not suffer from interference by prior BCG vaccination, which can cause false positives for TST. Thus, IGRA is preferred in populations that have high BCG vaccination coverage. Furthermore, IGRA tends to offer faster and more consistent results, meaning that patients require fewer visits, enhancing overall efficiency in testing. Growing penetration of these tests in high-risk populations, such as patients who are immunocompromised and health care workers, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in TB and advancements in diagnostics are also driving the high growth of the IGRA test segment in the latent TB testing market.

“Household contacts with pulmonary TB segment accounted for the highest growth rate in the latent TB testing market, by application, during the forecast period.”

Based on application, the latent TB testing market is bifurcated into household contacts (HHC) with pulmonary tuberculosis (TB)/household contacts (HHC) of tuberculosis (TB) patients, people living with HIV, and other applications. The household contacts with pulmonary TB application segment is expected to have the highest CAGR during the forecast period. Individuals in close contact with a TB patient have a much higher probability of becoming infected with latent TB, which is the reason why regular screenings are crucial in being able to diagnose the illness early and intervene by taking preventive measures. Increasing recognition of the critical role that latent TB testing plays among high-risk groups by healthcare providers and public health agencies also drives the need for accurate latent TB diagnostics. In addition, screening of contacts across the households by the governments and TB control programs in efforts to curb latent infections from becoming active TB is further driving growth in the market segment. Collectively, all these factors are contributing to the fast growth of this application within the latent TB testing market.

“Asia Pacific: The fastest-growing region in latent TB testing market.”

The worldwide market for latent TB testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drive the need for essential latent TB screening and management. Growth in government and international organization funding and campaigns against TB has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of latent TB has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the latent TB testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the latent TB testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the latent TB testing market:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US),  bioMérieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK).

Research Coverage:

This research report categorizes the latent TB testing market by test type (tuberculin skin test (TST) and interferon gamma release assay (IGRA)),  by application (household contacts with pulmonary TB, people living with HIV, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the latent TB testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the latent TB testing market. Competitive analysis of upcoming startups in the latent TB testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall latent TB testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising incidence of latent tuberculosis, widespread use of BCG vaccine, and increased funding and grants for TB control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the latent TB testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the latent TB testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the latent TB testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the latent TB testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), and Endo, Inc. (US).

Table of Contents

1            INTRODUCTION            25

1.1         STUDY OBJECTIVES      25

1.2         MARKET DEFINITION   25

1.3         STUDY SCOPE  26

1.3.1      MARKETS COVERED     26

1.3.2      INCLUSIONS & EXCLUSIONS     27

1.3.3      YEARS CONSIDERED     27

1.3.4      CURRENCY CONSIDERED          28

1.4         STAKEHOLDERS            28

2            RESEARCH METHODOLOGY     29

2.1         RESEARCH DATA           29

2.1.1      SECONDARY DATA       30

2.1.1.1   Key secondary sources       30

2.1.1.2   Key data from secondary sources     31

2.1.1.3   Objectives of secondary research     31

2.1.2      PRIMARY DATA 32

2.1.2.1   Key primary sources           32

2.1.2.2   Key data from primary sources         33

2.1.2.3   Key industry insights          34

2.1.2.4   Breakdown of primaries     34

2.1.2.4.1 Breakdown of primary interviews: supply & demand-side           34

2.1.2.4.2 Breakdown of primary interviews: by company type, designation, and region              35

2.2         MARKET SIZE ESTIMATION       35

2.2.1      BOTTOM-UP APPROACH           36

2.2.1.1   Company revenue estimation approach         36

2.2.1.2   Presentations of companies and primary interviews     36

2.2.1.3   Growth forecast   37

2.2.1.4   CAGR projections             37

2.2.2      TOP-DOWN APPROACH             37

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    39

2.4         MARKET SHARE ANALYSIS         39

2.5         ASSUMPTIONS 40

2.5.1      STUDY ASSUMPTIONS  40

2.5.2      GROWTH RATE ASSUMPTIONS 40

2.6         LIMITATIONS   41

2.7         RISK ASSESSMENT         41

3            EXECUTIVE SUMMARY 42

4            PREMIUM INSIGHTS      46

4.1         LATENT TB TESTING MARKET OVERVIEW         46

4.2         LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029      46

4.3         LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 47

4.4         LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029       47

4.5         LATENT TB TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           48

5            MARKET OVERVIEW     49

5.1         INTRODUCTION            49

5.2         MARKET DYNAMICS     49

5.2.1      DRIVERS            50

5.2.1.1   Rising incidence of latent tuberculosis           50

5.2.1.2   Widespread use of BCG vaccine      51

5.2.1.3   Increased funding and grants for TB control programs 52

5.2.2      RESTRAINTS     53

5.2.2.1   Unfavorable reimbursement scenario             53

5.2.3      OPPORTUNITIES           53

5.2.3.1   Growth opportunities in emerging economies 53

5.2.4      CHALLENGES   54

5.2.4.1   Changing regulatory landscape        54

5.2.4.2   Operational barriers and labor shortage         54

5.3         PRICING ANALYSIS        54

5.3.1      AVERAGE SELLING PRICE, BY PRODUCT            55

5.3.2      INDICATIVE PRICE OF IGRA TESTS, BY REGION 55

5.4         PATENT ANALYSIS        56

5.4.1      LIST OF MAJOR PATENTS          58

5.5         VALUE CHAIN ANALYSIS            59

5.6         SUPPLY CHAIN ANALYSIS          60

5.7         TRADE ANALYSIS          61

5.7.1      IMPORT DATA 62

5.7.2      EXPORT DATA 62

5.8         ECOSYSTEM ANALYSIS 63

5.8.1      ROLE IN ECOSYSTEM    64

5.9         PORTER’S FIVE FORCES ANALYSIS         64

5.9.1      THREAT OF NEW ENTRANTS    65

5.9.2      THREAT OF SUBSTITUTES         65

5.9.3      BARGAINING POWER OF BUYERS           66

5.9.4      BARGAINING POWER OF SUPPLIERS     66

5.9.5      INTENSITY OF COMPETITIVE RIVALRY 66

5.10       KEY STAKEHOLDERS AND BUYING CRITERIA    66

5.10.1    KEY STAKEHOLDERS IN BUYING PROCESS         67

5.10.2    KEY BUYING CRITERIA 67

5.11       REGULATORY ANALYSIS            68

5.11.1    REGULATORY LANDSCAPE       68

5.11.1.1 North America     68

5.11.1.1.1            US         68

5.11.1.1.2            Canada  68

5.11.1.2 Europe  69

5.11.1.2.1            Germany             69

5.11.1.2.2            UK         70

5.11.1.2.3            France   70

5.11.1.2.4            Italy       70

5.11.1.2.5            Spain     70

5.11.1.3 Asia Pacific          71

5.11.1.3.1            China     71

5.11.1.3.2            Japan     71

5.11.1.3.3            India      71

5.11.1.3.4            Australia 72

5.11.1.3.5            South Korea        72

5.11.1.3.6            Singapore            73

5.11.1.4 Latin America      73

5.11.1.4.1            Brazil     73

5.11.1.4.2            Mexico  74

5.11.1.5 Middle East         74

5.11.1.5.1            Africa    74

5.11.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          74

5.11.2.1 North America     74

5.11.2.2 Europe  75

5.11.2.3 Asia Pacific          75

5.11.2.4 Latin America      76

5.11.2.5 Rest of the world  76

5.12       TECHNOLOGY ANALYSIS           76

5.12.1    KEY TECHNOLOGIES    77

5.12.1.1 Tuberculin skin test           77

5.12.2    COMPLEMENTARY TECHNOLOGIES     77

5.12.2.1 Interferon gamma released assay     77

5.13       KEY CONFERENCES AND EVENTS, 2024–2025     78

5.14       TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS       79

5.15       INVESTMENT & FUNDING SCENARIO    79

5.16       CASE STUDY ANALYSIS 80

5.16.1    CASE STUDY 1: EXPLORING CYTOKINE USAGE IN MONITORING LTBI TREATMENT    80

5.16.2    CASE STUDY 2: ASSESSING DIAGNOSTIC ACCURACY OF ESAT6-CFP10 (EC) SKIN TEST FOR LTBI DETECTION 81

5.16.3    CASE STUDY 3: EVALUATING MTB-SPECIFIC CYTOKINE RESPONSES FOR ENHANCED LTBI DETECTION IN HEU INFANTS     81

5.17       LATENT TB CONTROL STRATEGIES IN MAJOR COUNTRIES       82

5.17.1    NORTH AMERICA          82

5.17.1.1 US         82

5.17.1.2 Canada  83

5.17.2    EUROPE             83

5.17.2.1 Germany             83

5.17.2.2 UK         84

5.17.3    ASIA PACIFIC    84

5.17.3.1 Japan     84

5.17.3.2 China     85

5.17.3.3 India      86

5.17.3.4 Singapore            87

5.18       IMPACT OF AI ON LATENT TB TESTING MARKET          87

5.18.1    KEY USE CASES 89

6            LATENT TB TESTING MARKET, BY TEST TYPE  90

6.1         INTRODUCTION            91

6.2         IGRA     91

6.2.1      HIGHER SPECIFICITY AND ACCURACY TO BOOST MARKET SEGMENT              91

6.3         TST       96

6.3.1      COST-EFFECTIVENESS TO PROPEL MARKET GROWTH 96

7            LATENT TB TESTING MARKET, BY APPLICATION          101

7.1         INTRODUCTION            102

7.2         PEOPLE LIVING WITH HIV         102

7.2.1      RISING RATES OF TB-HIV COINFECTION TO PROPEL GROWTH 102

7.3         HOUSEHOLD CONTACTS (HHC) WITH PULMONARY TUBERCULOSIS (TB)/ HOUSEHOLD CONTACTS (HHC) OF TUBERCULOSIS (TB) PATIENTS              106

7.3.1      NEED FOR ROUTINE SCREENING FOR HOUSEHOLD CONTACTS TO BOOST SEGMENT          106

7.4         OTHER APPLICATIONS 110

8            LATENT TB TESTING MARKET, BY END USER    115

8.1         INTRODUCTION            116

8.2         DIAGNOSTIC LABORATORIES   116

8.2.1      WELL-DEVELOPED INFRASTRUCTURE AND CAPABILITIES TO SUPPORT DEMAND FOR TESTING METHODS   116

8.3         HOSPITALS & CLINICS  120

8.3.1      GROWING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT 120

8.4         ACADEMIC & RESEARCH INSTITUTES   124

8.4.1      RISING INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH        124

8.5         OTHER END USERS        127

9            LATENT TB TESTING MARKET, BY REGION       131

9.1         INTRODUCTION            132

9.2         NORTH AMERICA          132

9.2.1      NORTH AMERICA: MACROECONOMIC OUTLOOK          133

9.2.2      US         136

9.2.2.1   US to dominate North American latent TB testing market         136

9.2.3      CANADA            140

9.2.3.1   Improved screening and treatment for latent TB to drive market             140

9.3         ASIA PACIFIC    142

9.3.1      ASIA PACIFIC: MACROECONOMIC OUTLOOK    143

9.3.2      CHINA  146

9.3.2.1   Growing public access to modern healthcare to fuel market growth          146

9.3.3      JAPAN  149

9.3.3.1   Presence of universal healthcare reimbursement policy to drive market    149

9.3.4      INDIA   151

9.3.4.1   High TB burden and growing government initiatives to drive demand for latent TB screening       151

9.3.5      SOUTH KOREA 154

9.3.5.1   Rising healthcare spending in innovative diagnostic technologies to support market growth     154

9.3.6      AUSTRALIA       157

9.3.6.1   Diverse immigrant population to fuel demand for latent TB screening     157

9.3.7      SINGAPORE      159

9.3.7.1   Enhanced healthcare infrastructure to propel market growth     159

9.3.8      REST OF ASIA PACIFIC  162

9.4         EUROPE             164

9.4.1      EUROPE: MACROECONOMIC OUTLOOK            164

9.4.2      UK         167

9.4.2.1   Growing number of diagnostic centers to fuel market  167

9.4.3      FRANCE             169

9.4.3.1   Presence of robust healthcare system to augment market growth             169

9.4.4      GERMANY         171

9.4.4.1   Higher healthcare spending and favorable government policies to favor market growth   171

9.4.5      SPAIN   174

9.4.5.1   Improving healthcare infrastructure to drive demand   174

9.4.6      ITALY   176

9.4.6.1   Improved quality of medical care to spur market growth            176

9.4.7      BELGIUM          178

9.4.7.1   Targeted screening for high-risk groups to fuel demand             178

9.4.8      SWEDEN            180

9.4.8.1   Growing immigrant population from high-prevalence regions to propel demand              180

9.4.9      DENMARK         182

9.4.9.1   Importance of latent TB testing in public health strategy to support market growth              182

9.4.10    REST OF EUROPE           184

9.5         LATIN AMERICA             186

9.5.1      LATIN AMERICA: MACROECONOMIC OUTLOOK            187

9.5.2      BRAZIL 189

9.5.2.1   Developed public health systems and improving healthcare infrastructure to favor market growth     189

9.5.3      MEXICO             191

9.5.3.1   Modernization of healthcare infrastructure to augment market growth     191

9.5.4      REST OF LATIN AMERICA          194

9.6         MIDDLE EAST & AFRICA             196

9.6.1      MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK            196

9.6.2      SOUTH AFRICA 198

9.6.2.1   Rising government initiatives for TB screening to augment market growth              198

9.6.3      SAUDI ARABIA  201

9.6.3.1   Enhancements in healthcare infrastructure to support market growth      201

9.6.4      UAE      203

9.6.4.1   UAE ranks among the world’s leading countries with low TB rates           203

9.6.5      KUWAIT             205

9.6.5.1   Expansion of healthcare infrastructure to augment market growth           205

9.6.6      REST OF MIDDLE EAST & AFRICA           207

10          COMPETITIVE LANDSCAPE       210

10.1       INTRODUCTION            210

10.2       KEY PLAYER STRATEGIES/RIGHT TO WIN          210

10.2.1    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATENT TB TESTING MARKET         210

10.3       REVENUE SHARE ANALYSIS       212

10.4       MARKET SHARE ANALYSIS         213

10.4.1    MARKET SHARE ANALYSIS, BY REGION 215

10.4.1.1 North America     215

10.4.1.2 Europe  215

10.4.1.3 Asia Pacific          216

10.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   216

10.5.1    STARS  216

10.5.2    EMERGING LEADERS    216

10.5.3    PERVASIVE PLAYERS     216

10.5.4    PARTICIPANTS 216

10.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      218

10.5.5.1 Company footprint            218

10.5.5.2 Test type footprint             218

10.5.5.3 Application footprint         218

10.5.5.4 Region footprint  219

10.6       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          219

10.6.1    PROGRESSIVE COMPANIES       219

10.6.2    RESPONSIVE COMPANIES          219

10.6.3    DYNAMIC COMPANIES 219

10.6.4    STARTING BLOCKS       219

10.7       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          221

10.7.1    COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023              221

10.8       VALUATION & FINANCIAL METRICS      222

10.9       BRAND/PRODUCT COMPARATIVE ANALYSIS    223

10.9.1    QIAGEN             223

10.9.2    REVVITY            223

10.9.3    BIOMÉRIEUX    224

10.10     COMPETITIVE SCENARIO          224

10.10.1  PRODUCT LAUNCHES  224

10.10.2  DEALS  225

11          COMPANY PROFILES    227

11.1       KEY PLAYERS   227

11.1.1    QIAGEN             227

11.1.1.1 Business overview 227

11.1.1.2 Products offered  228

11.1.1.3 Recent developments         229

11.1.1.3.1            Product launches & approvals          229

11.1.1.3.2            Deals     229

11.1.1.3.3            Expansions          230

11.1.1.4 MnM view           230

11.1.1.4.1            Right to win         230

11.1.1.4.2            Strategic choices  230

11.1.1.4.3            Weaknesses & competitive threats   230

11.1.2    REVVITY (OXFORD IMMUNOTEC)         231

11.1.2.1 Business overview 231

11.1.2.2 Products offered  232

11.1.2.3 Recent developments         233

11.1.2.3.1            Product launches & approvals          233

11.1.2.4 MnM view           233

11.1.2.4.1            Right to win         233

11.1.2.4.2            Strategic choices  233

11.1.2.4.3            Weaknesses & competitive threats   234

11.1.3    BEIJING WANTAI BIOPHARMACEUTICAL CO., LTD.       235

11.1.3.1 Business overview 235

11.1.3.2 Products offered  236

11.1.3.3 MnM view           236

11.1.3.3.1            Right to win         236

11.1.3.3.2            Strategic choices  236

11.1.3.3.3            Weaknesses & competitive threats   236

11.1.4    SANOFI 237

11.1.4.1 Business overview 237

11.1.4.2 MnM view           239

11.1.4.2.1            Right to win         239

11.1.4.2.2            Strategic choices  239

11.1.4.2.3            Weaknesses & competitive threats   239

11.1.5    ENDO, INC.        240

11.1.5.1 Business overview 240

11.1.5.2 Products offered  241

11.1.5.3 MnM view           241

11.1.5.3.1            Key strengths       241

11.1.5.3.2            Strategic choices  241

11.1.5.3.3            Weaknesses and competitive threats 241

11.1.6    BIOMÉRIEUX    242

11.1.6.1 Business overview 242

11.1.6.2 Products offered  243

11.1.6.3 Recent developments         244

11.1.6.3.1            Product approvals 244

11.1.7    SD BIOSENSOR, INC.      245

11.1.7.1 Business overview 245

11.1.7.2 Products offered  246

11.1.7.3 Recent developments         246

11.1.7.3.1            Deals     246

11.1.8    LIONEX GMBH 247

11.1.8.1 Business overview 247

11.1.8.2 Products offered  247

11.1.9    SERUM INSTITUTE OF INDIA PVT. LTD.              248

11.1.9.1 Business overview 248

11.1.9.2 Products offered  248

11.1.10  ARKRAY, INC.    249

11.1.10.1             Business overview 249

11.1.10.2             Products offered  249

11.1.10.3             Recent developments         250

11.1.10.3.1          Expansions          250

11.2       OTHER PLAYERS           250

11.2.1    ZHI FEI BIOLOGICAL    250

11.2.2    AID AUTOIMMUN DIAGNOSTIKA GMBH            251

11.2.3    BODITECH MED INC.    251

11.2.4    BIONEOVAN CO., LTD. 252

11.2.5    BIOPANDA REAGENTS LTD.      252

12          APPENDIX         253

12.1       DISCUSSION GUIDE      253

12.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             257

12.3       CUSTOMIZATION OPTIONS      259

12.4       RELATED REPORTS       259

12.5       AUTHOR DETAILS         260

LIST OF TABLES

TABLE 1             LATENT TB TESTING MARKET: RISK ASSESSMENT         41

TABLE 2             COMMERCIALLY AVAILABLE IGRA TESTS, BY KEY PLAYER              51

TABLE 3             AVERAGE SELLING PRICE OF LATENT TB TESTS, 2022–2024              55

TABLE 4             INDICATIVE PRICE OF IGRA TESTS, BY REGION, 2022–2024              56

TABLE 5             LATENT TB TESTING MARKET: LIST OF MAJOR PATENTS, 2022–2023          58

TABLE 6             IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)    62

TABLE 7             EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION)    62

TABLE 8             LATENT TB TESTING MARKET: ROLE IN ECOSYSTEM   64

TABLE 9             LATENT TB TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS          64

TABLE 10           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS (%)  67

TABLE 11           KEY BUYING CRITERIA FOR LATENT TB TESTS, BY TYPE              68

TABLE 12           CLASSIFICATION OF DEVICES IN EUROPE          69

TABLE 13           JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS           71

TABLE 14           AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES              72

TABLE 15           NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 74

TABLE 16           EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 75

TABLE 17           ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 75

TABLE 18           LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 76

TABLE 19           REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 76

TABLE 20           LATENT TB TESTING MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS          78

TABLE 21           LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)          91

TABLE 22           LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)        91

TABLE 23           BCG VACCINATION COVERAGE, BY REGION, 2021 VS 2022 VS 2023 (%)             93

TABLE 24           COMMERCIALLY AVAILABLE IGRA PRODUCTS, BY COMPANY              93

TABLE 25           LATENT TB TESTING MARKET FOR IGRA, BY REGION, 2022–2029 (USD MILLION)     94

TABLE 26           NORTH AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,

2022–2029 (USD MILLION)          94

TABLE 27           EUROPE: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,

2022–2029 (USD MILLION)          95

TABLE 28           ASIA PACIFIC: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,

2022–2029 (USD MILLION)          95

TABLE 29           LATIN AMERICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY,

2022–2029 (USD MILLION)          96

TABLE 30           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR IGRA, BY COUNTRY, 2022–2029 (USD MILLION) 96

TABLE 31           COMMERCIALLY AVAILABLE TST PRODUCTS IN MARKET, BY COMPANY         97

TABLE 32           LATENT TB TESTING MARKET FOR TST, BY REGION, 2022–2029 (USD MILLION) 98

TABLE 33           NORTH AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,

2022–2029 (USD MILLION)          98

TABLE 34           EUROPE: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,

2022–2029 (USD MILLION)          99

TABLE 35           ASIA PACIFIC: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,

2022–2029 (USD MILLION)          99

TABLE 36           LATIN AMERICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY,

2022–2029 (USD MILLION)          100

TABLE 37           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR TST, BY COUNTRY, 2022–2029 (USD MILLION)   100

TABLE 38           LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 102

TABLE 39           LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY REGION,

2022–2029 (USD MILLION)          103

TABLE 40           NORTH AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,

BY COUNTRY, 2022–2029 (USD MILLION)            104

TABLE 41           EUROPE: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,

BY COUNTRY, 2022–2029 (USD MILLION)            104

TABLE 42           ASIA PACIFIC: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,

BY COUNTRY, 2022–2029 (USD MILLION)            105

TABLE 43           LATIN AMERICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV,

BY COUNTRY, 2022–2029 (USD MILLION)            105

TABLE 44           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR PEOPLE LIVING WITH HIV, BY COUNTRY, 2022–2029 (USD MILLION)     106

TABLE 45           LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY REGION, 2022–2029 (USD MILLION) 108

TABLE 46           NORTH AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION) 108

TABLE 47           EUROPE: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION)              109

TABLE 48           ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION) 109

TABLE 49           LATIN AMERICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION) 110

TABLE 50           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOUSEHOLD CONTACTS WITH PULMONARY TB, BY COUNTRY, 2022–2029 (USD MILLION) 110

TABLE 51           LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY REGION,

2022–2029 (USD MILLION)          111

TABLE 52           NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)            112

TABLE 53           EUROPE: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)            112

TABLE 54           ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)            113

TABLE 55           LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)            113

TABLE 56           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)           114

TABLE 57           LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)          116

TABLE 58           LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 118

TABLE 59           NORTH AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              118

TABLE 60           EUROPE: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES,

BY COUNTRY, 2022–2029 (USD MILLION)            119

TABLE 61           ASIA PACIFIC: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES,

BY COUNTRY, 2022–2029 (USD MILLION)            119

TABLE 62           LATIN AMERICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              120

TABLE 63           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              120

TABLE 64           US: NUMBER OF COMMUNITY HOSPITALS, 2020 –VS 2021              122

TABLE 65           LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION,

2022–2029 (USD MILLION)          122

TABLE 66           NORTH AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2029 (USD MILLION)            122

TABLE 67           EUROPE: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)         123

TABLE 68           ASIA PACIFIC: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2029 (USD MILLION)            123

TABLE 69           LATIN AMERICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2022–2029 (USD MILLION)            124

TABLE 70           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)            124

TABLE 71           LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES,

BY REGION, 2022–2029 (USD MILLION)  125

TABLE 72           NORTH AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              125

TABLE 73           EUROPE: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          126

TABLE 74           ASIA PACIFIC: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)       126

TABLE 75           LATIN AMERICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              127

TABLE 76           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              127

TABLE 77           LATENT TB TESTING MARKET FOR OTHER END USERS, BY REGION,

2022–2029 (USD MILLION)          128

TABLE 78           NORTH AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)            128

TABLE 79           EUROPE: LATENT TB TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)             129

TABLE 80           ASIA PACIFIC: LATENT TB TESTING MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)            129

TABLE 81           LATIN AMERICA: LATENT TB TESTING MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)            130

TABLE 82           MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)            130

TABLE 83           LATENT TB TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)          132

TABLE 84           NORTH AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET         134

TABLE 85           NORTH AMERICA: LATENT TB TESTING MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          135

TABLE 86           NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          135

TABLE 87           NORTH AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            135

TABLE 88           NORTH AMERICA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          136

TABLE 89           NORTH AMERICA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          136

TABLE 90           US: MAIN TB/LTBI INSTITUTIONS          138

TABLE 91           US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 138

TABLE 92           US: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS) 139

TABLE 93           US: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     139

TABLE 94           US: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 139

TABLE 95           CANADA: MAIN TB/LTBI INSTITUTIONS             141

TABLE 96           CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     141

TABLE 97           CANADA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       141

TABLE 98           CANADA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          142

TABLE 99           CANADA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     142

TABLE 100         ASIA PACIFIC: MACROECONOMIC INDICATORS FOR LATENT TB TESTING MARKET   144

TABLE 101         ASIA PACIFIC: LATENT TB TESTING MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          145

TABLE 102         ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          145

TABLE 103         ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            145

TABLE 104         ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          146

TABLE 105         ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          146

TABLE 106         CHINA: MAIN TB/LTBI INSTITUTIONS  147

TABLE 107         CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     148

TABLE 108         CHINA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       148

TABLE 109         CHINA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          148

TABLE 110         CHINA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     149

TABLE 111         JAPAN: MAIN TB/LTBI INSTITUTIONS   150

TABLE 112         JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     150

TABLE 113         JAPAN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       150

TABLE 114         JAPAN: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          151

TABLE 115         JAPAN: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 151

TABLE 116         INDIA: MAIN TB/LTBI INSTITUTIONS    153

TABLE 117         INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     153

TABLE 118         INDIA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       153

TABLE 119         INDIA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     154

TABLE 120         INDIA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 154

TABLE 121         SOUTH KOREA: MAIN TB/LTBI INSTITUTIONS  155

TABLE 122         SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          156

TABLE 123         SOUTH KOREA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            156

TABLE 124         SOUTH KOREA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          156

TABLE 125         SOUTH KOREA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          157

TABLE 126         AUSTRALIA: MAIN TB/LTBI INSTITUTIONS        158

TABLE 127         AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          158

TABLE 128         AUSTRALIA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            158

TABLE 129         AUSTRALIA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          159

TABLE 130         AUSTRALIA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          159

TABLE 131         SINGAPORE: MAIN TB/LTBI INSTITUTIONS       160

TABLE 132         SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          160

TABLE 133         SINGAPORE: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)          161

TABLE 134         SINGAPORE: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          161

TABLE 135         SINGAPORE: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          161

TABLE 136         REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          162

TABLE 137         REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            163

TABLE 138         REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          163

TABLE 139         REST OF ASIA PACIFIC: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          163

TABLE 140         EUROPE: MACROINDICATORS FOR LATENT TB TESTING MARKET            165

TABLE 141         EUROPE: LATENT TB TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     165

TABLE 142         EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     166

TABLE 143         EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       166

TABLE 144         EUROPE: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          166

TABLE 145         EUROPE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     167

TABLE 146         UK: MAIN TB/LTBI INSTITUTIONS         168

TABLE 147         UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 168

TABLE 148         UK: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS) 168

TABLE 149         UK: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     169

TABLE 150         UK: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 169

TABLE 151         FRANCE: MAIN TB/LTBI INSTITUTIONS              170

TABLE 152         FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     170

TABLE 153         FRANCE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       170

TABLE 154         FRANCE: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          171

TABLE 155         FRANCE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     171

TABLE 156         GERMANY: MAIN TB/LTBI INSTITUTIONS          172

TABLE 157         GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          172

TABLE 158         GERMANY: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            173

TABLE 159         GERMANY: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          173

TABLE 160         GERMANY: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          173

TABLE 161         SPAIN: MAIN TB/LTBI INSTITUTIONS    174

TABLE 162         SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     174

TABLE 163         SPAIN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       175

TABLE 164         SPAIN: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     175

TABLE 165         SPAIN: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 175

TABLE 166         ITALY: MAIN TB/LTBI INSTITUTIONS    176

TABLE 167         ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     176

TABLE 168         ITALY: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       177

TABLE 169         ITALY: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     177

TABLE 170         ITALY: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 177

TABLE 171         BELGIUM: MAIN TB/LTBI INSTITUTIONS           178

TABLE 172         BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          178

TABLE 173         BELGIUM: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       179

TABLE 174         BELGIUM: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          179

TABLE 175         BELGIUM: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          179

TABLE 176         SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          180

TABLE 177         SWEDEN: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       181

TABLE 178         SWEDEN: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          181

TABLE 179         SWEDEN: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          181

TABLE 180         DENMARK: MAIN TB/LTBI INSTITUTIONS          182

TABLE 181         DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          182

TABLE 182         DENMARK: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            183

TABLE 183         DENMARK: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          183

TABLE 184         DENMARK: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          183

TABLE 185         REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          184

TABLE 186         REST OF EUROPE: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            185

TABLE 187         REST OF EUROPE: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          185

TABLE 188         REST OF EUROPE: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          185

TABLE 189         LATIN AMERICA: MACROINDICATORS FOR LATENT TB TESTING MARKET         187

TABLE 190         LATIN AMERICA: LATENT TB TESTING MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          187

TABLE 191        LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          188

TABLE 192        LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)          188

TABLE 193         LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          188

TABLE 194         LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          189

TABLE 195         BRAZIL: MAIN TB/LTBI INSTITUTIONS 190

TABLE 196         BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     190

TABLE 197         BRAZIL: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       190

TABLE 198         BRAZIL: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          191

TABLE 199         BRAZIL: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     191

TABLE 200         MEXICO: MAIN TB/LTBI INSTITUTIONS              192

TABLE 201         MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     192

TABLE 202         MEXICO: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       193

TABLE 203         MEXICO: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          193

TABLE 204         MEXICO: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     193

TABLE 205         REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          194

TABLE 206         REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            195

TABLE 207         REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          195

TABLE 208         REST OF LATIN AMERICA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          195

TABLE 209         MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          197

TABLE 210         MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          197

TABLE 211         MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            197

TABLE 212         MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          198

TABLE 213         MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          198

TABLE 214         SOUTH AFRICA: MAIN TB/LTBI INSTITUTIONS 199

TABLE 215         SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          200

TABLE 216         SOUTH AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            200

TABLE 217         SOUTH AFRICA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          200

TABLE 218         SOUTH AFRICA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          201

TABLE 219         SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (USD MILLION)          202

TABLE 220         SAUDI ARABIA: LATENT TB TESTING MARKET, BY TEST TYPE,

2022–2029 (IN MILLIONS)            202

TABLE 221         SAUDI ARABIA: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          202

TABLE 222         SAUDI ARABIA: LATENT TB TESTING MARKET, BY END USER,

2022–2029 (USD MILLION)          203

TABLE 223         UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 204

TABLE 224         UAE: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS) 204

TABLE 225         UAE: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     204

TABLE 226         UAE: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 205

TABLE 227         KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)     206

TABLE 228         KUWAIT: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)       206

TABLE 229         KUWAIT: LATENT TB TESTING MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          206

TABLE 230         KUWAIT: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)     207

TABLE 231         REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)       208

TABLE 232         REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY TEST TYPE, 2022–2029 (IN MILLIONS)         208

TABLE 233         REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION)  208

TABLE 234         REST OF MIDDLE EAST & AFRICA: LATENT TB TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)         209

TABLE 235         OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES             210

TABLE 236         LATENT TB TESTING MARKET: DEGREE OF COMPETITION              213

TABLE 237         LATENT TB TESTING MARKET: TEST TYPE FOOTPRINT              218

TABLE 238         LATENT TB TESTING MARKET: APPLICATION FOOTPRINT              218

TABLE 239         LATENT TB TESTING MARKET: REGION FOOTPRINT    219

TABLE 240         LATENT TB TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS          221

TABLE 241         LATENT TB TESTING MARKET: COMPETITIVE BENCHMARKING

OF STARTUP/SME PLAYERS      221

TABLE 242         LATENT TB TESTING MARKET: PRODUCT LAUNCHES,

JANUARY 2021–SEPTEMBER 2024            224

TABLE 243         LATENT TB TESTING MARKET: DEALS, JANUARY 2021–SEPTEMBER 2024           225

TABLE 244         QIAGEN: COMPANY OVERVIEW 227

TABLE 245         QIAGEN: PRODUCTS OFFERED 228

TABLE 246         QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024           229

TABLE 247         QIAGEN: DEALS, JANUARY 2021–SEPTEMBER 2024          229

TABLE 248         QIAGEN: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024              230

TABLE 249         REVVITY: COMPANY OVERVIEW            231

TABLE 250         REVVITY: PRODUCTS OFFERED             232

TABLE 251         REVVITY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024           233

TABLE 252         BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY OVERVIEW        235

TABLE 253         BEIJING WANTAI BIOPHARMACEUTICAL: PRODUCTS OFFERED          236

TABLE 254         SANOFI: COMPANY OVERVIEW 237

TABLE 255         SANOFI: PRODUCTS OFFERED 238

TABLE 256         ENDO: COMPANY OVERVIEW   240

TABLE 257         ENDO: PRODUCTS OFFERED    241

TABLE 258         BIOMÉRIEUX: COMPANY OVERVIEW     242

TABLE 259         BIOMÉRIEUX: PRODUCTS OFFERED      243

TABLE 260         BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021–SEPTEMBER 2024           244

TABLE 261         SD BIOSENSOR: COMPANY OVERVIEW 245

TABLE 262         SD BIOSENSOR: PRODUCTS OFFERED  246

TABLE 263         SD BIOSENSOR: DEALS, JANUARY 2021–SEPTEMBER 2024              246

TABLE 264         LIONEX GMBH: COMPANY OVERVIEW  247

TABLE 265         LIONEX GMBH: PRODUCTS OFFERED   247

TABLE 266         SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW     248

TABLE 267         SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED      248

TABLE 268         ARKRAY: COMPANY OVERVIEW 249

TABLE 269         ARKRAY: PRODUCTS OFFERED 249

TABLE 270         ARKRAY: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024              250

LIST OF FIGURES

FIGURE 1           LATENT TB TESTING MARKET: RESEARCH DESIGN       29

FIGURE 2           BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH       36

FIGURE 3           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   37

FIGURE 4           LATENT TB TESTING MARKET: TOP-DOWN APPROACH              38

FIGURE 5           LATENT TB TESTING MARKET: DATA TRIANGULATION              39

FIGURE 6           LATENT TB TESTING MARKET: STUDY ASSUMPTIONS 40

FIGURE 7           LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION) 42

FIGURE 8           LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 43

FIGURE 9           LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 43

FIGURE 10         LATENT TB TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)          44

FIGURE 11         INCREASING PREVALENCE OF LATENT TB AND GROWING FINANCIAL

SUPPORT FOR TB CONTROL TO DRIVE MARKET           46

FIGURE 12         IGRA WILL CONTINUE TO DOMINATE MARKET TILL 2029              46

FIGURE 13         PEOPLE LIVING WITH HIV SEGMENT TO HOLD LARGEST MARKET SHARE             47

FIGURE 14         DIAGNOSTIC LABORATORIES SEGMENT TO RETAIN DOMINANT

MARKET SHARE TILL 2029         47

FIGURE 15         ASIA PACIFIC TO REGISTER HIGHEST GROWTH             48

FIGURE 16         LATENT TB TESTING MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES    49

FIGURE 17         PATENT ANALYSIS FOR LATENT TB TESTS (JANUARY 2014–DECEMBER 2023)           57

FIGURE 18         VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES      59

FIGURE 19         LATENT TB TESTING MARKET: SUPPLY CHAIN ANALYSIS              60

FIGURE 20         LATENT TB TESTING MARKET: ECOSYSTEM ANALYSIS 63

FIGURE 21         LATENT TB TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS          65

FIGURE 22         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LATENT TB TESTS         67

FIGURE 23         KEY BUYING CRITERIA FOR LATENT TB TESTS 67

FIGURE 24         TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS              79

FIGURE 25         DEALS AND FUNDING IN LATENT TB TESTING MARKET              80

FIGURE 26         MARKET POTENTIAL OF AI TO ENHANCE R&D IN LATENT TB TESTING MARKET         88

FIGURE 27         NORTH AMERICA: LATENT TB TESTING MARKET SNAPSHOT              134

FIGURE 28         ASIA PACIFIC: LATENT TB TESTING MARKET SNAPSHOT              144

FIGURE 29         REVENUE ANALYSIS OF KEY PLAYERS IN LATENT TB TESTING MARKET

(2021–2023)       212

FIGURE 30         MARKET SHARE ANALYSIS OF KEY PLAYERS IN LATENT TB

TESTING MARKET (2023)           213

FIGURE 31         NORTH AMERICA: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)   215

FIGURE 32         EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)              215

FIGURE 33         ASIA PACIFIC: MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)   216

FIGURE 34         LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023     217

FIGURE 35         LATENT TB TESTING MARKET: COMPANY FOOTPRINT 218

FIGURE 36         LATENT TB TESTING MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2023             220

FIGURE 37         EV/EBITDA OF KEY VENDORS   222

FIGURE 38         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 222

FIGURE 39         BRAND COMPARISON FOR IGRA            223

FIGURE 40         QIAGEN: COMPANY SNAPSHOT (2023)  228

FIGURE 41         REVVITY: COMPANY SNAPSHOT (2023) 232

FIGURE 42         BEIJING WANTAI BIOPHARMACEUTICAL: COMPANY SNAPSHOT (2023)          235

FIGURE 43         SANOFI: COMPANY SNAPSHOT (2023)   238

FIGURE 44         ENDO: COMPANY SNAPSHOT (2023)     240

FIGURE 45         BIOMÉRIEUX: COMPANY SNAPSHOT (2023)       243

FIGURE 46         SD BIOSENSOR: COMPANY SNAPSHOT (2023)    245

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧